Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03407573
Other study ID # WKRO-2016-0018
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 1, 2017
Est. completion date June 1, 2019

Study information

Verified date March 2018
Source NHS Lothian
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The investigator wishes to see if it is possible to undertake a study comparing blood transfusion at two different levels of anaemia to see which is best for patients. All patients that present to hospital with a broken hip will be able to take part in the study. If they become anaemic during their treatment they will be allocated to either be transfused when their blood count is less that 9 or less than 7. In all patients, we will measure heart damage with a blood test that is very sensitive. The investigator will also collect data on the incidence of heart attacks and other complications.


Description:

Many frail and elderly patients undergo surgery for hip fractures every year. Many of these patients have other health problems including heart disease and anaemia (low haemoglobin or "low blood count") either from chronic illness, from bleeding at the time of their injury or during subsequent surgery. The vast majority (more than 95%) of these patients will go on to have surgery. This surgery is often high risk. Patients with this type of injury may already be frail, may be in hospital for a long time and will need rehabilitation. Many of them will develop complications, including heart attacks and some will die.

Doctors looking after these patients commonly prescribe a blood transfusion around the time of surgery. These patient often have anaemia before surgery an lose more blood during their operations. A benefit of blood transfusion is that it may increase the amount of oxygen the blood can carry. One of the main reasons that doctors prescribe blood around the time of surgery is to prevent heart attacks, which can occur if the heart doesn't receive enough oxygen. Another possible benefit of blood transfusion is that it may help patients get out of bed more quickly after surgery. This is another important aspect of their recovery.

However, blood transfusions can have side effects such as causing heart failure or increasing infections after surgery. These can delay patient recovery too. Although some research has been done in this area, anaesthetists and surgeons are still unsure of when to prescribe blood transfusions to these patients. In particular, uncertainty about how low the blood count should be before a blood transfusion is ordered. Some doctors prescribe blood when the haemoglobin count is less than 9 and some at a lower level of 7. Current guidelines suggest that prescribing at a lower haemoglobin count is better, but there is research which suggests that this level is too low if the patient has a history of heart disease.


Recruitment information / eligibility

Status Completed
Enrollment 200
Est. completion date June 1, 2019
Est. primary completion date March 1, 2019
Accepts healthy volunteers No
Gender All
Age group 50 Years and older
Eligibility Inclusion Criteria:Adults aged over 50 years Within 48 hours of admission to hospital with fractured Neck of Femur. Exclusion Criteria: Age <50

- Refusal of consent of patient (or consultee) Patient for palliative care.

Study Design


Intervention

Biological:
Administration of Red Cell
Transfusion of red cells dependent on haemoglobin level. Either transfused at haemoglobin of 7 or 9.

Locations

Country Name City State
United Kingdom Royal Hospital for Sick Children Edinburgh

Sponsors (1)

Lead Sponsor Collaborator
NHS Lothian

Country where clinical trial is conducted

United Kingdom, 

References & Publications (4)

Acheson AG, Brookes MJ, Spahn DR. Effects of allogeneic red blood cell transfusions on clinical outcomes in patients undergoing colorectal cancer surgery: a systematic review and meta-analysis. Ann Surg. 2012 Aug;256(2):235-44. doi: 10.1097/SLA.0b013e31825b35d5. Review. — View Citation

Davenport DL, Bowe EA, Henderson WG, Khuri SF, Mentzer RM Jr. National Surgical Quality Improvement Program (NSQIP) risk factors can be used to validate American Society of Anesthesiologists Physical Status Classification (ASA PS) levels. Ann Surg. 2006 M — View Citation

Fowler AJ, Ahmad T, Phull MK, Allard S, Gillies MA, Pearse RM. Meta-analysis of the association between preoperative anaemia and mortality after surgery. Br J Surg. 2015 Oct;102(11):1314-24. doi: 10.1002/bjs.9861. Review. — View Citation

Holst LB, Petersen MW, Haase N, Perner A, Wetterslev J. Restrictive versus liberal transfusion strategy for red blood cell transfusion: systematic review of randomised trials with meta-analysis and trial sequential analysis. BMJ. 2015 Mar 24;350:h1354. do — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Troponin Peak troponin concentration within 7 days of surgery (ngL )
Other Troponin -Time Area under a Troponin-Time curve within 7 days of surgery
Other Red cells transfused Number of units red cells transfused within7 days of surgery and within 30 days of surgery or before hospital discharge, whichever occurs first.
Other Volume in mls of Red Cells Transfused. Volume of red blood cells transfused in mls within 7 days of surgery and within 30 days of surgery or before hospital discharge, whichever occurs first.
Other Haemoglobin postoperatively Postoperative Hb on postoperative days days 1,3,5,7 after surgery
Other Nadir Hb Nadir Hb within 7 days of surgery and within 30 days of surgery or before hospital discharge, whichever occurs first.
Other Hospital Admission Duration of hospital admission (days) from admission to discharge date from hospital upto 60 days.
Other Readmission to hospital Incidence of unplanned hospital readmission within 60 days upto 60 days of hospital discharge date
Other Destination Discharge destination (home, other hospital, nursing home, other) at Discharge from hospital with fractured hip upto 60 days of admission
Other Health Related Quality of Life HRQoL at 60 days (EQ 5D) at 60 days after surgery
Other Costs Secondary care costs during 60 days post-randomisation in Great British Pound 60 days post randomisation
Primary Myocardial Injury Myocardial injury defined as a high sensitivity cardiac Troponin 1 (Troponin) concentration above the upper reference limit [URL] OF 16 ng L and 34 ng L in women and men respectively at any time during the study period. Upto 60 days
Secondary Myocardial Infarction Myocardial Infarction defined per the universal definition within 30 days of surgery or before hospital discharge, whichever occurs first. within 30 days of surgery
Secondary Mortality Mortality (30; 60 days from day of surgery). upto 60 days following surgery
Secondary Diagnosis of Major Adverse Cardiac Events New diagnosis of MACE within 30 days of surgery or before hospital discharge, whichever occurs first. within 30 days or before hospital discharge
Secondary Acute Kidney Injury New diagnosis of Acute Kidney Injury within 30 days of surgery or before discharge from hospital whichever occurs first.
Secondary Infections New diagnosis of Infectious Complications within 30 days of surgery or before hospital discharge, whichever is first.
Secondary Delirium New diagnosis of Delirium within 30 days of surgery or before hospital discharge, whichever occurs first.
See also
  Status Clinical Trial Phase
Terminated NCT00801931 - Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders Phase 1/Phase 2
Completed NCT02948283 - Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia Phase 1
Completed NCT03341338 - Genes-in-Action - Hepcidin Regulation of Iron Supplementation
Completed NCT00060398 - Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer Phase 3
Recruiting NCT05384691 - Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions Phase 2
Not yet recruiting NCT06309641 - Methemoglobinemia Following Intravenous Iron Treatment
Completed NCT02930850 - Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation N/A
Completed NCT02888171 - Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency N/A
Completed NCT03822884 - Pharmacokinetic/Pharmacodynamic Study of 3 Subcutaneous Single Dose Epoetin Alfa Formulations in Healthy Volunteers Phase 1
Completed NCT02912533 - A Long-term Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD) Phase 3
Completed NCT02912494 - A Phase III Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD) Phase 3
Completed NCT02384122 - Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias Phase 3
Completed NCT02603250 - Evaluation of Hemoglobin Measurement Tools for Child Anemia Screening in Rwanda N/A
Completed NCT02176759 - Iron Absorption From Rice Fortified With Ferric Pyrophosphate N/A
Withdrawn NCT01934842 - A Study to Compare Analyte Levels in Blood Collected Using an Investigational Collection Device With a Commercial Predicate N/A
Completed NCT01922479 - Pilot Study of Ferric Carboxymaltose to Treat Iron Deficiency in Asians With Heart Failure Phase 4
Completed NCT02310113 - Transfusion and Skeletal Muscle Tissue Oxygenation N/A
Completed NCT01693029 - Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa Phase 3
Terminated NCT01535781 - Study of the Effect of Tranexamic Acid Administered to Patients With Hip Fractures. Can Blood Loss be Reduced? N/A
Completed NCT01458028 - Age and Gender Effects on the Pharmacokinetics of BAY85-3934 Phase 1